Streetbeat News

Analyst Ratings

PGR

B of A Securities has maintained a Buy rating on Progressive (NYSE:PGR) and raised its price target from $294 to $312, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 1:03 pm

OSTX

EF Hutton has initiated coverage on OS Therapies (AMEX:OSTX) with a Buy rating and set a price target of $21. This suggests a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 1:01 pm

PGY

Analysts have mixed ratings for Pagaya Techs (NASDAQ:PGY), with a range of bullish to bearish sentiments. The average 12-month price target is $24.86, a decrease from the previous $26.00. Pagaya Techs shows strong revenue growth but faces challenges with net margin, ROE, and debt management.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 1:01 pm

JPM

JPMorgan Chase (NYSE:JPM) has been analyzed by 12 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target has increased to $221.75, with a high of $239.00 and a low of $210.00. Recent analyst actions include several rating upgrades and price target increases, reflecting positive sentiment towards JPMorgan's financial performance, which includes strong revenue growth and profitability metrics.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 1:00 pm

IIIV

i3 Verticals (NASDAQ:IIIV) has been analyzed by 7 analysts, showing a range of opinions from bullish to somewhat bullish. The average 12-month price target is $30.29, up 1.44% from the previous target. Analysts have adjusted their ratings and price targets, reflecting their views on the company's performance. Despite a decline in revenue, i3 Verticals shows strong net margin and ROE, but has a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 1:00 pm

TXG

11 analysts have recently evaluated 10x Genomics (NASDAQ:TXG), showing mixed sentiments. The average 12-month price target has decreased by 32.5% to $27.0. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Despite a strong revenue growth rate of 4.28%, 10x Genomics faces challenges with negative net margin, ROE, and ROA, but maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 1:00 pm

ALL

Allstate (NYSE:ALL) has received 16 analyst ratings in the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $200.06, indicating a positive outlook. Despite revenue growth, Allstate faces challenges with profitability and debt management.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 1:00 pm

CRDO

Credo Technology Group (NASDAQ:CRDO) has received bullish ratings from four analysts in the past three months, with a notable increase in the average 12-month price target to $37.75. Analysts have raised their price targets, reflecting positive sentiment despite the company's challenges with profitability and returns.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 1:00 pm

HCP

Citigroup analyst Fatima Boolani has reinstated a Neutral rating on HashiCorp (NASDAQ:HCP) and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:57 pm